ventac partners general presentation 2015

Driving Innova+on And Strategic Excellence in the Life Sciences

www.ventac-‐partners.com

Why Ventac For Your Life Science Company?

2

•  Real-‐World Opera+onal Experience •  Corporate Strategies •  New Business Models

•  Market & IP Research •  Compe++ve & Pipeline Analysis •  Start-‐ups, spin-‐outs and early stage •  Due Diligence •  Business Development •  Product Development Planning

We Bring Real-‐World, Current Experience To Address Your Analy+cal And Opera+onal Needs

2

Real-‐World Experience

We Start And Operate New Life Science Companies

Innova+on

Venture Capital

Management

•  Ventac Partners iden+fies early-‐stage assets and technologies from academic and corporate sources

•  Hundreds of opportuni+es are reviewed before seUling on the best ones with the greatest chance of success

•  Ventac Partners creates a new company which licenses the technology

•  Ventac Partners prepares the business plan and obtains seed funding from investors

•  Ventac Partners creates a 2-‐4 person management team who work for company for equity and low monthly fees

•  Efficient model means investment is focused on product development, not salaries nor expensive labs/offices

We Start And Build Companies Via A Cost-‐effec+ve Opera+onal Model

4

Prac+cing What We Preach

• We perform market opportunity assessments for our own por[olio opportuni+es and build data-‐rich business cases.

• We run out-‐licensing and fund-‐raising processes for our por[olio companies…we know what investors and partners are seeking.

• We manage our own companies, so our management and turn-‐around experiences are real, current, and effec+ve.

Our Advice Is Legi+mate Because We Start And Operate Our Own Companies

5

Market Research

Market Research: Founda+on For Everything We Do We Deploy GlobalData And Other Tools For Market Research

7

•  Compe++ve Intelligence Analysis •  Disease area strategy and treatment dynamics •  Market Assessment •  Pipeline landscape analysis •  Epidemiology assessments •  KOL interviews •  Product SWOT and Opportunity Analysis

Always Focused on Value Crea+on

8

•  Commercial Valida+on • We evaluate commercial opportuni+es for early-‐stage assets •  Primary and secondary research to build business case •  Supported by industry and investment community feedback

•  Business Crea+on • We build the business plan, fundraise and execute, focusing on value crea+on

• We facilitate new company forma+on, partnering and out-‐licensing to industry

•  Our direct experience makes this possible

•  Training • We can provide training for management and entrepreneurs •  Commercializa+on, licensing, valua+on, patent strategies and company forma+on

•  Based on real-‐world, current informa+on and experiences

8

We Leverage Our Experiences To Develop The Business Strategy

Business Development & Related Services

We Serve Investors And Their Companies

• We can provide independent, second opinions on valua+ons, product and market opportuni+es, and compe++ve intelligence

• We run out-‐licensing and fund-‐raising processes for our por[olio companies…we know what investors and partners are seeking.

• We can advise por[olio companies on product development plans, from Preclinical through Phase IV.

We Work With Investors And Por[olio Companies On A Daily Basis

10

We Understand The Need To Drive Towards Exits

•  Founded 2003 •  Partnerships with Enzon, GSK, Wyeth, Shire

•  Acquired for $250 million upfront and an addi+onal con+ngent payments of $200 million

•  Danish opera+ons to be renamed Roche Innova+on Center Copenhagen

The Recent Acquisi+on Of Santaris By Roche Provided An AUrac+ve Exit For Ventac And Investors

11

Partners Select Track Record

Financing * M&A *

$200,000,000

Strategic Alliance & License

2006

Licensing *

$900,000,000 $380,000,000

2009

$11,500,000

2013

$58,500,000

2010

$500,000,000

2011

$917,000,000

2013

$50,000,000

2006 $450,000,000

Acquisition by

2014

$7,500,000

Merged with

2003

*Including transac/on completed by partners before joining Ventac Partners

$21,800,000

2013

$348,000,000

2013 $1,800,000,000

2013






Strategic Alliance & License Strategic Alliance &

License

Strategic Alliance & License Strategic Alliance &

License


Series B

2007

2008

$30,000,000

2007 $14,000,000

2012

F-1 Prepared

2014

Series C

Preparation for IPO at NASDAQ

Dual Track / M&A by Roche

Series D

$Not disclosed

2007

Co-ownership & License

Professor Imanishi &

Pantheco

$Not disclosed

Acquisition of 8 drugs 2013

$6,700,000

2012 Strategic Alliance

& License

$10,000,000

2000

Private Placement to a consortium of Nordic Investors

Lead Manager

$13,000,000

2001

Private Placement to a consortium of Nordic Investors Sole

Manager

$Not disclosed

2000 Worldwide rights to

LNA technology

$180,000,000

2000

Worldwide semi-exlusive

manufacturing rights to LNA technology

$Not disclosed

2000

Use of LNA in clinical diagnostics

$23,000,000

2004

$10,500,000

2006

$17,000,000

2003

Series B Private

Financing

Series C Private

Financing

Private Financing

$400,000,000

2005


$4,000,000

2014

Series A

$10,300,000

2006 Series A

(2nd closing)

$47,000,000

2009 Series B

$35,000,000.

2000

Novartis Research

Foundation Partnership

$Not disclosed

Merged with

2014 $Not disclosed

Acquisition of

2014

$700,000,000

2007

$Not disclosed

2009

$10,000,000

2010-2014

$Not disclosed

2004

$Not disclosed

2008

Raises Sarsia Seeds &

Series A + B financing



Raises Sarsia Seeds &

Series A, B & C financing

$2,100,000

2015

Listing on Swedish Stock Exchange

$Not disclosed

2011 $Not disclosed

Strategc Alliance & License

2011

Miacom Diagnos+cs

We’ve done it before…

Our Team

21 Partners and 14 offices on 3 Con+nents

Lund Copenhagen

Basel Madrid

Hong Kong

Boulder Boston Munich

Helsinki

Vienna Düsseldorf

Shanghai New York

We Work Where You Do – And Provide Global Reach

19

San Francisco (2016)

London

Selected Biographies Of Our Ventac Partners

• Mikael Oerum – Copenhagen •  Founder, Ventac Partners •  Current CEO, Avexxin •  Board Chair, HUNT Biosciences, others

• Melya Hughes Crameri – London •  Former CEO Evolva US, Caltherix •  BD Amunix, Novar+s Res. Founda+on •  Ph.D., Cardiff University; EPA

• Mar+n Aus+n – Basel •  Former Head of BD, Roche •  Former Principal, Paul Capital •  Author of mul+ple BD texts & courses

•  Peter Damsbo -‐ Copenhagen •  Former Chief Medical Officer, Zealand Pharma and VP Clinical Drug Development, Novo Nordisk

• MD; Preclin./Clinical Dev. exper+se

•  Kostas Alevizopoulos – Basel •  CSO & CEO of several companies •  Implements Preclinical development •  Ph.D., Molecular Biology, Lausanne

• ScoU Woodward—San Francisco • 15 years Life Science BD Experience • CEO (US) European Biomarker Co. • VP Biomarkers Global CRO • MS (Biochemistry), MA, MBA

We Have The Experience To Consult And/Or Manage Companies In The Life Sciences

15

ScoU Woodward, Partner Ventac Partners – Copenhagen and San Francisco

sbwoodward@ventac-‐partners.com +45 2329 4552

Contact

ventac partners general presentation 2015

Healthcare